Efficacy of BRAF‐Inhibitor Therapy in BRAF(V600E)‐Mutated Adult Langerhans Cell Histiocytosis

Langerhans cell histiocytosis (LCH) is a rare histiocytic neoplasm. To date, there is a lack of U.S. Food and Drug Administration–approved treatments in adult LCH to establish optimal first‐line therapy. We conducted a retrospective, single‐center case series evaluating the use of BRAF inhibitors in...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncologist
Main Authors: Hazim, Antonious Z., Ruan, Gordon J., Ravindran, Aishwarya, Abeykoon, Jithma P., Scheckel, Caleb, Vassallo, Robert, Ryu, Jay H., Tobin, W. Oliver, Koster, Matthew J., Bennani, N. Nora, Rech, Karen L., Young, Jason R., Shah, Mithun V., Goyal, Gaurav, Go, Ronald S.
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley & Sons, Inc. 2020
Assuntos:
Commentary
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7938396/
https://ncbi.nlm.nih.gov/pubmed/32985015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13541
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares